

CLEARBRIDGE HEALTH LIMITED
(Company Registration No.: 201001436C)
(Incorporated in the Republic of Singapore)

PROFIT GUIDANCE FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2025

The board of directors (the "**Board**") of Clearbridge Health Limited (the "**Company**" and together with its subsidiaries, the "**Group**") wishes to announce that, following a preliminary review of the Group's unaudited financial results for the financial year ended 31 December 2025 ("**FY2025**") and based on information currently available to the Board, the Group is expected to report a significantly higher net loss for FY2025, mainly attributable to:

- (i) the additional impairment of goodwill recognised for FY2025. The impairment was made based on the preliminary assessment of the current value-in-use of the relevant cash generating units, which was determined by discounting the pre-tax future cash flows to be generated from the continued use of the cash generating units, as compared to of the current carrying value of the cash generating units recorded in the balance sheet. As a result, there is also a significant impairment recorded for the Company's investment in its subsidiaries; and
- (ii) the fair value loss of the convertible exchangeable bonds recognised for FY2025, which arose as a result of a decrease in equity value of the bond issuer derived from the discounted cashflow projections which had been adjusted due to lower-than-expected performance by the bond issuer in FY2025.

The above impairment of goodwill and fair value loss are non-cash items.

The Company is still in the process of finalising its financial results for FY2025 and will provide further details of the Group's financial performance when it releases the unaudited financial results on or before 1 March 2026. Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company. Persons who are in doubt as to the action they should take should consult their stockbrokers, bankers, solicitors, accountants or other professional advisers.

BY ORDER OF THE BOARD

Yee Pinh Jeremy
Executive Director and Chief Executive Officer

23 February 2026

*This announcement has been reviewed by the Company's sponsor, UOB Kay Hian Private Limited (the "**Sponsor**").*

*This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited ("**SGX-ST**") and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

The contact person for the Sponsor is Mr Lance Tan, Senior Vice President, at 83 Clemenceau Avenue, #10-01 UE Square, Singapore 239920, telephone (65) 6590 6881.